Bellerophon Therapeutics Inc

Bellerophon Therapeutics — Investor Presentation (January 2019)

29 slides from Bellerophon Therapeutics's investor presentation, Jan 7, 2019

  1. Slide 1: Bellerophon Therapeutics Company Presentation January 2019

    Bellerophon Therapeutics Company Presentation I January 2019 January 2019 |

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi

  3. Slide 3: Bellerophon Therapeutics (BLPH) Company Profile

    Bellerophon Therapeutics (BLPH) Company Profile Company spun-off from Ikaria Clinical-Stage Biotherapeutics Focused on developing inhaled nitric oxide (iNO) based therapies for outpatient management of chronic pulmonary diseases Company Portable, lightweight delivery system allows for chronic home u

  4. Slide 4: Highly Experienced Leadership Team

    Highly Experienced Leadership Team Jonathan Peacock 10 years experience as CFO at Amgen Chairman and Novartis Pharma Fabian Tenenbaum 15 years of executive-level experience in Chief Executive Officer finance, BD and operations 20 years experience in clinical research Hunter Gillies, M.D. specializin

  5. Slide 5: Development Pipeline

    Development Pipeline Development Stage Indication Market Key Milestones 2018 2019 2020 Phase 2a Trial completed 220,000 with ILD in US Results presented in May 2017 35-40% with associated PH Phase 2b Trial: iNO-PF PH-ILD iNO-PF Ph 2b C1 C2 C3 Cohort 1 positive results presented (WHO Group 3) Unmet m

  6. Slide 6: INOpulse Delivery System Overview

    INOpulse Delivery System Overview Portable Delivery System Allows Chronic iNO Therapy Portable pulsatile iNO delivery system for chronic administration Novel drug-device combination therapy with dual mechanisms of action Targeted pulmonary vasodilation Ventilation/Perfusion (V/Q) matching NO Nitric

  7. Slide 7: INOpulse Delivery System Lightweight, Portable and User Friendly

    INOpulse Delivery System Lightweight, Portable and User Friendly Cannula Drug & Battery Key & Connector Power Indicators Alarm Swing engagement with drug 01 cartridge Intuitive and simple user 02 interface Oxygen Sources Tri-lumen cannula allows direct 03 connection with oxygen Lightweight portable

  8. Slide 8: INOpulse Provides a Unique and Differentiating Mechanism of Action

    INOpulse Provides a Unique and Differentiating Mechanism of Action Baseline Hypoxic pulmonary vasoconstriction prevents oxygen desaturation Systemic Vasodilators Systemic vasodilators can reverse hypoxic vasoconstriction leading to ventilation/perfusion (V/Q) mismatch and arterial O2 desaturation IN

  9. Slide 9: Interstitial Lung Disease (PH-ILD) A Significant Unmet Medical Need

    Interstitial Lung Disease (PH-ILD) A Significant Unmet Medical Need Normal Interstitial Lung Disease (ILD) is a broad category of diffuse lung diseases characterized by variable amounts of inflammation and fibrosis Idiopathic Pulmonary Fibrosis (IPF) is the largest and most serious of the many fibro

  10. Slide 10: PH-ILD Significantly Reduces Survival

    PH-ILD Significantly Reduces Survival Pulmonary hypertension as predictor of Approximately 40% of IPF patients exhibit symptoms of pulmonary survival in IPF hypertension at rest, including elevated pulmonary pressures Prognosis and survival are significantly worse for patients with pulmonary hyperte

  11. Slide 11: Phase 2a Study PH-IPF Acute Phase Data Showed Immediate Benefit

    Phase 2a Study PH-IPF Acute Phase Data Showed Immediate Benefit of iNO on Vasodilation and Hemodynamics • Significant correlation between ventilation and vasodilation, demonstrating selective vasodilation to better ventilated areas of the lung (p=0.009) • Consistent and clinically meaningful reducti

  12. Slide 12: Phase 2b (iNO-PF) Study Allows Assessment of Multiple Doses and Duration

    Phase 2b (iNO-PF) Study Allows Assessment of Multiple Doses and Duration of Treatment Double-blind placebo controlled study will assess 80 subjects with pulmonary fibrosis at low or intermediate/high risk of associated pulmonary hypertension • Endpoints include actigraphy, oxygen saturation, right v

  13. Slide 13: Summary of Key Outputs from iNO-PF Phase 2b Trial (Cohort 1)

    Summary of Key Outputs from iNO-PF Phase 2b Trial (Cohort 1) iNO Placebo Actigraphy (% change) • Moderate Activity (walking, stairs, +8% -26% • Statistically significant reduction in moderate activity for yardwork, etc.) placebo (p=0.04) • Overall Activity +0% -12% • Statistically significant reduct

  14. Slide 14: iNO Demonstrated Consistent and Sustained Benefit in Activity Parameters

    iNO Demonstrated Consistent and Sustained Benefit in Activity Parameters Moderate Activity Overall Activity Error bars are Standard Error January 2019 | 14

  15. Slide 15: Actigraphy in Clinical Trials

    Actigraphy in Clinical Trials • Actigraphy utilizes a wearable medical-grade activity monitor to continuously measure activity • Multiple late stage trials in cardiopulmonary disease are using actigraphy as the primary endpoint • Strong KOL support for activity monitoring to assess patient outcomes

  16. Slide 16: PH-ILD Market Opportunity in the US

    PH-ILD Market Opportunity in the US PH-ILD 220,000 ILD patients in the US IPF represents 44% of ILD patients 88% of PH-IPF patients Estimated prevalence of PH is 35-40% estimated to be on LTOT Prevalence of PH increases with severity of underlying lung disease Patients that are asymptomatic at rest

  17. Slide 17: Chronic Obstructive Pulmonary Disease (PH-COPD) A Large Unmet Medical Need

    Chronic Obstructive Pulmonary Disease (PH-COPD) A Large Unmet Medical Need Chronic obstructive pulmonary disease (COPD) which includes chronic bronchitis and emphysema is a group of lung diseases characterized by progressive airflow obstruction and chronic airway inflammation COPD is typically assoc

  18. Slide 18: Pulmonary Hypertension Independently Predicts Reduced Survival in COPD

    Pulmonary Hypertension Independently Predicts Reduced Survival in Moderate- to-Severe COPD Pulmonary hypertension • COPD patients with Pulmonary Hypertension have poor as predictor of survival in COPD prognosis and QoL 5 Year Survival • Median life-expectancy is ~4 years with high mPAP < 25 mmHg: 63

  19. Slide 19: Demonstrated Benefit of Pulsed iNO on Vasodilation and Hemodynamics for COPD Patients

    Demonstrated Benefit of Pulsed iNO on Vasodilation and Hemodynamics for COPD Patients Baseline Corrected Change in Hemodynamics (Vonbank et al. 2003) Vonbank et al, 2003 2 50 PVRI (dynes Sustained hemodynamic benefits, at three months, of pulsed 0 0 -2 -50 iNO+O2 -4 -100 1 1 2 - • Reduced mPAP and P

  20. Slide 20: High-Resolution CT Imaging Study Demonstrated iNO Targets Pulmonary Vessels

    High-Resolution Computed Tomography Imaging Study Demonstrated iNO targets pulmonary vessels in PH-COPD patients Targeted Vasodilation Ventilation-Vasodilation Matching • Acute Treatment with iNO 30 mcg/kg IBW/hr for at least 20 minutes (n=6) • No significant drop in blood oxygenation (SpO2) • All s

  21. Slide 21: COPD-007 Phase 2a Study Showed Benefit of Chronic iNO Treatment

    COPD-007 Phase 2a Study Showed Benefit of Chronic iNO Treatment on Exercise Capability and Hemodynamics Subjects who completed 4 week chronic phase on iNO 30 showed: • Statistically significant increase in 6MWD at 2 weeks and 4 weeks (+50.7m) • Statistically and clinically significant decrease in sP

  22. Slide 22: Next Steps in PH-COPD

    Next Steps in PH-COPD Phase 2b study design reviewed and finalized with FDA Phase 2b study results Phase 2b study results will help finalize patient Double-blind, placebo-controlled, study in population, clinical endpoints and study size for approximately 90 PH-COPD patients Phase 3 Multiple endpoin

  23. Slide 23: PH-COPD Market Opportunity in the US

    PH-COPD Market Opportunity in the US Estimated COPD in US prevalence of Prevalence: 27.8 million pulmonary hypertension (PH) Diagnosed: 12.7 million (45.6%) in COPD is 27% • KOL feedback indicates high unmet medical need in PH-COPD • Addressable market estimated to be ~350,000 patients in the US • M

  24. Slide 24: Pulmonary Hypertension associated with Sarcoidosis (PH-Sarc)

    Pulmonary Hypertension associated with Sarcoidosis (PH-Sarc) An Orphan Unmet Medical Need Chest x-ray & CT of patient with PH-Sarc Sarcoidosis is characterized by the growth of inflammatory cells (granulomas) most commonly in the lungs or lymphatic tissues Prevalence of sarcoidosis is estimated at 2

  25. Slide 25: INOpulse MoA has the Potential to Provide Benefit to PH-Sarc Patients

    INOpulse MoA has the Potential to Provide Benefit to PH-Sarc Patients Inhaled nitric oxide has been shown to improve hemodynamics and exercise capacity in PH-Sarc Acute Hemodynamic Benefit on iNO Parameter % Change Systemic vasodilators exacerbate hypoxic vasoconstriction mPAP -18 ± 4 and cause hypo

  26. Slide 26: INOpulse Intellectual Property Protection

    INOpulse Intellectual Property Protection Patent Status Expiration Description US/EU: Issued Covers consistent delivery of prescribed dose Method of NO administration Jan 2027 Other Territories: Issued/Pending independent of respiratory rate Covers skipping breaths or modifying pulse volume to Breat

  27. Slide 27: Financial Summary

    Financial Summary Amount (in millions) Cash and Cash Equivalents and Marketable Securities $20.6(1) Restricted Cash $0.6(1) Debt $0(1) Shares Outstanding 58.7(1) Fully Diluted 97.7(1) 1) Amounts as of September 30, 2018 per Quarterly Report on Form 10-Q filed November 7, 2018 January 2019 | 27

  28. Slide 28: Investment Highlights

    Investment Highlights Established iNO Therapeutic Benefit  Approved for acute treatment of persistent pulmonary hypertension  Positive results from multiple Phase 2 studies support INOpulse MoA and benefit in PH-ILD, PH-COPD and PH- Sarcoidosis Advanced Clinical Stage Product INOpulse technology f

  29. Slide 29: Investor Contacts

    Investor Contacts Fabian Tenenbaum Chief Executive Officer [email protected] Brian Ritchie LifeSci Advisors [email protected] 212-915-2578 January 2019 |

Bellerophon Therapeutics — Investor Presentation (January 2019) on 6ix